StockData
Alzamend Neuro, Inc. logo

Alzamend Neuro, Inc. (ALZN) stock

ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 10, 2026Score 4/30
$1.04−0.09 (-7.96%)

Close on Nov 18, 2026Market cap $5.02MP/E –Yield –

Alzamend Neuro r&d expenses

Research and development expenses are spending on new products and technology.

Alzamend Neuro's R&D Expenses for the twelve months ending Jul 31, 2026 was $2.97M. For fiscal 2026 it was $3.63M, up 156.5% from the year before. The highest annual figure on record is $7.45M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Apr 30, 2026$3.63M+156.5%
FY2025Apr 30, 2025$1.41M-78.1%
FY2024Apr 30, 2024$6.46M-13.3%
FY2023Apr 30, 2023$7.45M+43.2%
FY2022Apr 30, 2022$5.20M+296.8%
FY2021Apr 30, 2021$1.31M+22.6%
FY2020Apr 30, 2020$1.07M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jul 31, 2026$1.09M-37.6%
Q4 FY2026CQ1 2026Apr 30, 2026$434.01K+110.1%
Q3 FY2026CQ4 2025Jan 31, 2026$1.28M+597.1%
Q2 FY2026CQ3 2025Oct 31, 2025$176.28K-90.8%
Q1 FY2026CQ2 2025Jul 31, 2025$1.74M-12.8%
Q1 FY2025CQ2 2024Jul 31, 2024$206.57K-91.3%
Q4 FY2024CQ1 2024Apr 30, 2024$183.43K-88.9%
Q3 FY2024CQ4 2023Jan 31, 2024$1.91M-33.9%
Q2 FY2024CQ3 2023Oct 31, 2023$2.00M+30.3%
Q1 FY2024CQ2 2023Jul 31, 2023$2.37M+72.0%
Q4 FY2023CQ1 2023Apr 30, 2023$1.65M-0.8%
Q3 FY2023CQ4 2022Jan 31, 2023$2.89M+230.7%
Q2 FY2023CQ3 2022Oct 31, 2022$1.53M-12.4%
Q1 FY2023CQ2 2022Jul 31, 2022$1.38M+50.1%
Q4 FY2022CQ1 2022Apr 30, 2022$1.66M+467.6%
Q3 FY2022CQ4 2021Jan 31, 2022$873.65K+272.9%
Q2 FY2022CQ3 2021Oct 31, 2021$1.75M+268.5%
Q1 FY2022CQ2 2021Jul 31, 2021$916.41K+196.7%
Q4 FY2021CQ1 2021Apr 30, 2021$292.70K–
Q3 FY2021CQ4 2020Jan 31, 2021$234.26K–
Q2 FY2021CQ3 2020Oct 31, 2020$474.91K–
Q1 FY2021CQ2 2020Jul 31, 2020$308.85K–

More Alzamend Neuro figures

See a number that looks wrong?